References:
Gwyer, D., Wragg, N. M., & Wilson, S. L. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 377(2), 153–159. https://pubmed.ncbi.nlm.nih.gov/30915550/
Menchaca, R. (2015). PCO-02 – Safety and pharmacokinetics trial (Clinical Trial No. NCT02637284). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT02637284
Operation Supplement Safety Program. (2024). BPC-157: A prohibited peptide and an unapproved drug found in health and wellness products. U.S. Department of Defense. https://www.opss.org/article/bpc-157-prohibited-peptide-and-unapproved-drug-found-health-and-wellness-products
U.S. Anti-Doping Agency. (2020). BPC-157: Experimental peptide creates risk for athletes. USADA. https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/
Vasireddi, N., Hahamyan, H., Salata, M. J., Karns, M., Calcei, J. G., Voos, J. E., & Apostolakos, J. M. (2025). Emerging use of BPC-157 in orthopaedic sports medicine: A systematic review. HSS Journal, Article 15563316251355551. https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605/